A lack of diversity in medical studies is hurting science and patients.
Researchers at the University of Washington believe that a similar approach could also prove invaluable for children born
But there is good reason to keep up hope. There are promising innovations on the horizon. An analysis of the Phase II/III
We are advancing grassroots participation in large-scale research initiations such as the Metastatic Breast Cancer Project
What would it look like if researchers, clinicians, and diagnostic and drug developers created an unprecedented model of collaboration and data sharing to solve one of the country's biggest challenges: cancer?
If you'd like to learn more about participating in the Generation Study, visit GeneMatch (www.endALZnow.org/GeneMatch), a
Yet transportation is a persistent issue. The Eliminating Disparities in Clinical Trials Project (EDICT) named unreliable
People with AD and their caregivers are already spending fortunes on FDA-approved medications that are ineffective. People with AD and their caregivers do not need any new false bottles of hope.
More than 44 million people across the globe have Alzheimer's disease. And that number is expected to multiply by three or more over the next several decades. Yet, despite billions of dollars of investments into research and advocacy for effective treatment and a cure, neither exists.
For years, clinical research has been unequal. There's been a lack of diversity in clinical trial participants for both the customer and provider side of medical science.